Noninvasive imaging of mGlu2 using positron emission tomography (PET) can visualize and provide quantitative measurement of the distribution and expression of this receptor under physiological and pathological conditions 36-40, further enabling a better understanding of the relationship between mGlu2 mediated glutamatergic signaling and CNS disorders. Here, GRM2 is linked to central nervous system disorder.